Search

Coloplast A-S (Class B)

Suletud

578.2 1.12

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

576.8

Max

579.6

Põhinäitajad

By Trading Economics

Sissetulek

70M

875M

Müük

2M

7B

P/E

Sektori keskmine

35.807

90.831

Aktsiakasum

3.88

Dividenditootlus

4.01

Kasumimarginaal

12.572

Töötajad

16,744

EBITDA

2B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+11.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.01%

2.20%

Järgmine tulemuste avaldamine

6. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

7.5B

130B

Eelmine avamishind

577.08

Eelmine sulgemishind

578.2

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. jaan 2026, 23:29 UTC

Kuumad aktsiad

Stocks to Watch: Atossa Therapeutics, Union Pacific

16. jaan 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16. jaan 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 21:48 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16. jaan 2026, 21:41 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16. jaan 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16. jaan 2026, 20:44 UTC

Tulu

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16. jaan 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16. jaan 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16. jaan 2026, 19:12 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16. jaan 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16. jaan 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16. jaan 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16. jaan 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16. jaan 2026, 16:32 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16. jaan 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK  11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

2

Osta

4

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat